EGFR and lung cancer: Three phosphorylation sites (Y1110, Y1172, and Y1197) connected to erlotinib sensitivity were validated using IP-SRM in lung cancer tissue samples; Y1197 phosphorylated peptides showed good signal, which confirmed that IP-SRM strategy is suitable for EGFR phosphorylation measurement.